Q-omics provides the consensus-scored GPM6A profile across patient tissues and cancer cell-line models. GPM6A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GPM6A is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, GPM6A RNA expression shows 20,733 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, THCA, and LSCC as cancer lineages where GPM6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPM6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPM6A survival associations across molecular data types. GPM6A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPM6A RNA expression–survival associations across cancer types. High GPM6A expression shows unfavorable associations in BLCA and LUSC, but favorable associations in BRCA, KIRC, LIHC and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for GPM6A RNA expression.
This table summarizes GPM6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPM6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPM6A shows lower tumor expression in THCA, KICH, COAD, LUAD, LUSC and KIRP. The THCA box plot shows higher GPM6A RNA expression in normal versus tumor tissue (log2 FC = −3.474, t-test p < 0.001).
This table shows molecular features associated with GPM6A in patient tissues and cancer cell lines. In patient samples, GPM6A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPM6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
